| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fractional Flow Reserve, Myocardial | 57 | 2025 | 58 | 24.150 |
Why?
|
| Percutaneous Coronary Intervention | 54 | 2025 | 58 | 21.290 |
Why?
|
| Coronary Artery Disease | 47 | 2026 | 85 | 17.350 |
Why?
|
| Coronary Stenosis | 36 | 2025 | 38 | 14.790 |
Why?
|
| Treatment Outcome | 77 | 2025 | 500 | 9.290 |
Why?
|
| Coronary Angiography | 52 | 2025 | 71 | 9.170 |
Why?
|
| Cardiac Catheterization | 36 | 2025 | 43 | 8.540 |
Why?
|
| Myocardial Infarction | 19 | 2026 | 46 | 8.480 |
Why?
|
| Humans | 155 | 2026 | 6794 | 7.910 |
Why?
|
| Coronary Vessels | 24 | 2025 | 44 | 6.300 |
Why?
|
| Angioplasty, Balloon, Coronary | 13 | 2026 | 15 | 4.870 |
Why?
|
| Radial Artery | 15 | 2025 | 15 | 4.780 |
Why?
|
| ST Elevation Myocardial Infarction | 8 | 2024 | 11 | 4.300 |
Why?
|
| Cardiology | 8 | 2024 | 15 | 3.590 |
Why?
|
| Hemodynamics | 15 | 2024 | 34 | 3.560 |
Why?
|
| Catheterization, Peripheral | 10 | 2025 | 11 | 3.290 |
Why?
|
| Predictive Value of Tests | 25 | 2025 | 127 | 3.070 |
Why?
|
| Ultrasonography, Interventional | 11 | 2025 | 17 | 3.030 |
Why?
|
| Femoral Artery | 10 | 2025 | 13 | 2.680 |
Why?
|
| Aortic Valve Stenosis | 4 | 2024 | 7 | 2.260 |
Why?
|
| Male | 47 | 2026 | 3671 | 2.180 |
Why?
|
| Coronary Artery Bypass | 7 | 2024 | 15 | 2.120 |
Why?
|
| Drug-Eluting Stents | 4 | 2022 | 7 | 1.940 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2019 | 17 | 1.920 |
Why?
|
| Electrocardiography | 5 | 2026 | 36 | 1.890 |
Why?
|
| Hemostatics | 3 | 2022 | 6 | 1.890 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2023 | 5 | 1.880 |
Why?
|
| Cardiac Catheters | 7 | 2025 | 7 | 1.800 |
Why?
|
| Female | 40 | 2026 | 4060 | 1.690 |
Why?
|
| Stents | 7 | 2025 | 13 | 1.660 |
Why?
|
| Diabetes Mellitus | 3 | 2022 | 208 | 1.630 |
Why?
|
| Atrial Fibrillation | 2 | 2024 | 16 | 1.580 |
Why?
|
| Atherectomy, Coronary | 2 | 2023 | 2 | 1.540 |
Why?
|
| Myocardial Revascularization | 7 | 2021 | 9 | 1.520 |
Why?
|
| Arterial Occlusive Diseases | 3 | 2022 | 4 | 1.470 |
Why?
|
| Angiography | 3 | 2023 | 15 | 1.430 |
Why?
|
| Tomography, Optical Coherence | 6 | 2025 | 48 | 1.420 |
Why?
|
| Myocardial Ischemia | 3 | 2022 | 9 | 1.420 |
Why?
|
| Coronary Circulation | 6 | 2024 | 8 | 1.370 |
Why?
|
| Troponin | 4 | 2017 | 4 | 1.360 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2025 | 82 | 1.320 |
Why?
|
| Middle Aged | 24 | 2026 | 2108 | 1.260 |
Why?
|
| Acute Coronary Syndrome | 5 | 2019 | 12 | 1.250 |
Why?
|
| Coronary Occlusion | 2 | 2023 | 2 | 1.220 |
Why?
|
| Emergency Medical Services | 2 | 2022 | 19 | 1.120 |
Why?
|
| Heart Failure | 4 | 2020 | 49 | 1.110 |
Why?
|
| Aged | 23 | 2026 | 1539 | 1.090 |
Why?
|
| Thrombosis | 2 | 2018 | 13 | 1.060 |
Why?
|
| Radiation Exposure | 3 | 2026 | 6 | 1.020 |
Why?
|
| Atherosclerosis | 2 | 2017 | 39 | 1.010 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 5 | 1.000 |
Why?
|
| Microcirculation | 2 | 2024 | 14 | 1.000 |
Why?
|
| Reproducibility of Results | 10 | 2025 | 112 | 0.990 |
Why?
|
| Hemorrhage | 5 | 2024 | 23 | 0.970 |
Why?
|
| Critical Illness | 1 | 2026 | 14 | 0.960 |
Why?
|
| Societies, Medical | 3 | 2020 | 67 | 0.910 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2016 | 3 | 0.900 |
Why?
|
| Patient Discharge | 4 | 2020 | 27 | 0.900 |
Why?
|
| Clinical Competence | 4 | 2024 | 51 | 0.900 |
Why?
|
| Coronary Thrombosis | 2 | 2017 | 3 | 0.890 |
Why?
|
| Tyrosine | 2 | 2017 | 5 | 0.890 |
Why?
|
| Punctures | 7 | 2025 | 7 | 0.880 |
Why?
|
| Femoral Vein | 1 | 2024 | 2 | 0.870 |
Why?
|
| Pacemaker, Artificial | 3 | 2019 | 3 | 0.870 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 4 | 0.840 |
Why?
|
| Coronary Disease | 2 | 2015 | 18 | 0.840 |
Why?
|
| Health Care Costs | 1 | 2024 | 30 | 0.830 |
Why?
|
| Contrast Media | 3 | 2025 | 18 | 0.830 |
Why?
|
| Biomarkers | 4 | 2019 | 214 | 0.820 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 4 | 0.820 |
Why?
|
| Registries | 6 | 2023 | 63 | 0.810 |
Why?
|
| Practice Guidelines as Topic | 4 | 2026 | 84 | 0.800 |
Why?
|
| Chylothorax | 1 | 2023 | 1 | 0.790 |
Why?
|
| Thoracic Duct | 1 | 2023 | 2 | 0.790 |
Why?
|
| Quality of Life | 2 | 2023 | 184 | 0.790 |
Why?
|
| Severity of Illness Index | 8 | 2024 | 118 | 0.780 |
Why?
|
| Risk Factors | 14 | 2026 | 767 | 0.770 |
Why?
|
| Adenosine | 3 | 2025 | 9 | 0.760 |
Why?
|
| Cardiovascular System | 1 | 2022 | 21 | 0.760 |
Why?
|
| Prospective Studies | 9 | 2025 | 331 | 0.750 |
Why?
|
| Exercise Test | 2 | 2019 | 9 | 0.750 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 4 | 0.740 |
Why?
|
| Pulmonary Embolism | 2 | 2020 | 6 | 0.740 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2019 | 16 | 0.700 |
Why?
|
| Baseball | 1 | 2021 | 1 | 0.690 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 27 | 0.680 |
Why?
|
| Axillary Artery | 1 | 2020 | 1 | 0.670 |
Why?
|
| Catheters | 3 | 2020 | 6 | 0.660 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 1 | 0.650 |
Why?
|
| Atrial Septum | 1 | 2020 | 1 | 0.650 |
Why?
|
| Kidney Failure, Chronic | 3 | 2023 | 420 | 0.640 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 2 | 0.640 |
Why?
|
| Sex Characteristics | 1 | 2020 | 39 | 0.630 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2019 | 1 | 0.620 |
Why?
|
| Atrioventricular Block | 1 | 2019 | 1 | 0.620 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2019 | 1 | 0.610 |
Why?
|
| Mitral Valve Stenosis | 1 | 2019 | 2 | 0.610 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 3 | 0.610 |
Why?
|
| Mitral Valve | 1 | 2019 | 4 | 0.610 |
Why?
|
| Crowdsourcing | 1 | 2019 | 1 | 0.610 |
Why?
|
| Smartphone | 1 | 2019 | 6 | 0.600 |
Why?
|
| Computer Simulation | 2 | 2016 | 26 | 0.600 |
Why?
|
| Calculi | 1 | 2019 | 1 | 0.600 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2019 | 1 | 0.600 |
Why?
|
| Arterial Pressure | 1 | 2018 | 2 | 0.590 |
Why?
|
| Length of Stay | 2 | 2019 | 53 | 0.580 |
Why?
|
| Thermodilution | 1 | 2018 | 1 | 0.580 |
Why?
|
| Ischemia | 2 | 2022 | 7 | 0.560 |
Why?
|
| Computed Tomography Angiography | 3 | 2025 | 16 | 0.540 |
Why?
|
| Constriction, Pathologic | 3 | 2024 | 9 | 0.540 |
Why?
|
| Tachycardia, Ventricular | 1 | 2017 | 2 | 0.530 |
Why?
|
| Mammary Arteries | 1 | 2017 | 1 | 0.530 |
Why?
|
| Ulnar Artery | 2 | 2019 | 2 | 0.530 |
Why?
|
| Ultrasonography | 4 | 2024 | 38 | 0.520 |
Why?
|
| Mechanical Thrombolysis | 1 | 2017 | 1 | 0.520 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 54 | 0.510 |
Why?
|
| Fibrinolysis | 1 | 2016 | 1 | 0.510 |
Why?
|
| Ioxaglic Acid | 1 | 2016 | 1 | 0.510 |
Why?
|
| Triiodobenzoic Acids | 1 | 2016 | 1 | 0.510 |
Why?
|
| Heart-Assist Devices | 1 | 2016 | 2 | 0.510 |
Why?
|
| Heparin | 3 | 2022 | 8 | 0.510 |
Why?
|
| Prognosis | 5 | 2021 | 220 | 0.500 |
Why?
|
| Retrospective Studies | 6 | 2026 | 681 | 0.500 |
Why?
|
| Vascular Malformations | 1 | 2016 | 3 | 0.500 |
Why?
|
| Fluoroscopy | 5 | 2026 | 7 | 0.500 |
Why?
|
| Echocardiography, Stress | 1 | 2016 | 1 | 0.500 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 3 | 0.490 |
Why?
|
| Adenosine Monophosphate | 1 | 2016 | 4 | 0.490 |
Why?
|
| Radiation Protection | 2 | 2026 | 4 | 0.490 |
Why?
|
| Occupational Exposure | 2 | 2026 | 12 | 0.480 |
Why?
|
| Hyperemia | 1 | 2016 | 1 | 0.480 |
Why?
|
| Radiation Injuries | 2 | 2026 | 9 | 0.480 |
Why?
|
| Hemostasis | 3 | 2022 | 3 | 0.480 |
Why?
|
| Hemostatic Techniques | 3 | 2022 | 4 | 0.470 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 25 | 0.470 |
Why?
|
| Heart Injuries | 1 | 2015 | 1 | 0.470 |
Why?
|
| Transducers, Pressure | 3 | 2020 | 4 | 0.460 |
Why?
|
| Creatinine | 1 | 2015 | 48 | 0.460 |
Why?
|
| Radiography, Interventional | 3 | 2026 | 5 | 0.460 |
Why?
|
| Vasodilator Agents | 3 | 2025 | 7 | 0.450 |
Why?
|
| Sirolimus | 1 | 2015 | 6 | 0.450 |
Why?
|
| Polymers | 1 | 2015 | 7 | 0.450 |
Why?
|
| United States | 11 | 2025 | 1019 | 0.440 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 6 | 0.440 |
Why?
|
| Hospitals, Veterans | 1 | 2014 | 9 | 0.440 |
Why?
|
| Time Factors | 8 | 2025 | 321 | 0.430 |
Why?
|
| Ventricular Function, Left | 3 | 2024 | 21 | 0.430 |
Why?
|
| Consensus | 4 | 2025 | 39 | 0.430 |
Why?
|
| Angina, Stable | 3 | 2019 | 3 | 0.430 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2014 | 4 | 0.430 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2014 | 3 | 0.430 |
Why?
|
| Robotics | 1 | 2014 | 3 | 0.430 |
Why?
|
| Vascular Closure Devices | 2 | 2024 | 2 | 0.430 |
Why?
|
| Peripheral Arterial Disease | 1 | 2014 | 4 | 0.420 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 7 | 0.410 |
Why?
|
| Medicare | 2 | 2019 | 57 | 0.400 |
Why?
|
| Pyridines | 1 | 2013 | 24 | 0.400 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2024 | 5 | 0.400 |
Why?
|
| Foundations | 1 | 2013 | 2 | 0.400 |
Why?
|
| Coronary Restenosis | 1 | 2013 | 2 | 0.390 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2013 | 4 | 0.390 |
Why?
|
| Advisory Committees | 1 | 2013 | 23 | 0.390 |
Why?
|
| Stroke Volume | 2 | 2024 | 20 | 0.390 |
Why?
|
| Creatine Kinase, MB Form | 3 | 2019 | 3 | 0.390 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2025 | 9 | 0.390 |
Why?
|
| Paclitaxel | 1 | 2013 | 14 | 0.390 |
Why?
|
| Workload | 1 | 2013 | 6 | 0.390 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2012 | 1 | 0.370 |
Why?
|
| Arteriosclerosis | 1 | 2012 | 10 | 0.370 |
Why?
|
| Quality Improvement | 2 | 2022 | 31 | 0.350 |
Why?
|
| Learning Curve | 2 | 2024 | 3 | 0.340 |
Why?
|
| Potassium Compounds | 2 | 2022 | 2 | 0.330 |
Why?
|
| Risk Assessment | 5 | 2026 | 197 | 0.330 |
Why?
|
| Iron Compounds | 2 | 2022 | 7 | 0.330 |
Why?
|
| Aortic Valve | 2 | 2020 | 4 | 0.310 |
Why?
|
| Clinical Decision-Making | 5 | 2025 | 18 | 0.310 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 8 | 0.300 |
Why?
|
| Specialization | 2 | 2019 | 17 | 0.300 |
Why?
|
| Myocardium | 2 | 2019 | 25 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 268 | 0.290 |
Why?
|
| Blood Pressure | 3 | 2020 | 112 | 0.290 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2008 | 1 | 0.280 |
Why?
|
| Heart Murmurs | 1 | 2008 | 1 | 0.280 |
Why?
|
| Sinus of Valsalva | 1 | 2008 | 1 | 0.280 |
Why?
|
| Aortic Rupture | 1 | 2008 | 2 | 0.280 |
Why?
|
| Anatomic Landmarks | 2 | 2018 | 4 | 0.270 |
Why?
|
| Postoperative Complications | 2 | 2019 | 109 | 0.270 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 79 | 0.250 |
Why?
|
| Occupational Injuries | 1 | 2026 | 2 | 0.240 |
Why?
|
| Musculoskeletal Diseases | 1 | 2026 | 4 | 0.240 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 42 | 0.240 |
Why?
|
| Vascular Calcification | 1 | 2026 | 12 | 0.240 |
Why?
|
| Patient Selection | 3 | 2025 | 40 | 0.240 |
Why?
|
| Surgicenters | 1 | 2025 | 1 | 0.240 |
Why?
|
| Cardiologists | 1 | 2025 | 3 | 0.240 |
Why?
|
| Angina Pectoris | 2 | 2023 | 4 | 0.230 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 36 | 0.230 |
Why?
|
| Suture Techniques | 1 | 2024 | 4 | 0.220 |
Why?
|
| Sutures | 1 | 2024 | 4 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 153 | 0.210 |
Why?
|
| Vascular Resistance | 1 | 2024 | 7 | 0.210 |
Why?
|
| Hypertension, Portal | 1 | 2024 | 3 | 0.210 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 48 | 0.210 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2014 | 7 | 0.200 |
Why?
|
| Veterans | 1 | 2024 | 70 | 0.200 |
Why?
|
| Equipment Design | 4 | 2026 | 20 | 0.190 |
Why?
|
| STAT2 Transcription Factor | 1 | 2022 | 1 | 0.190 |
Why?
|
| Chronic Disease | 1 | 2023 | 167 | 0.180 |
Why?
|
| Metals | 1 | 2022 | 2 | 0.180 |
Why?
|
| Communication | 1 | 2022 | 31 | 0.180 |
Why?
|
| Congresses as Topic | 2 | 2026 | 20 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 497 | 0.180 |
Why?
|
| Fee-for-Service Plans | 2 | 2019 | 8 | 0.180 |
Why?
|
| Shock, Cardiogenic | 1 | 2021 | 1 | 0.180 |
Why?
|
| Survivors | 1 | 2021 | 15 | 0.180 |
Why?
|
| Dilatation | 1 | 2021 | 2 | 0.170 |
Why?
|
| Diffusion of Innovation | 2 | 2020 | 7 | 0.170 |
Why?
|
| Axilla | 1 | 2020 | 2 | 0.170 |
Why?
|
| Incidence | 2 | 2019 | 197 | 0.170 |
Why?
|
| Collateral Circulation | 1 | 2020 | 1 | 0.170 |
Why?
|
| Heart Diseases | 1 | 2020 | 9 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 7 | 0.160 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 7 | 0.160 |
Why?
|
| Echocardiography | 1 | 2020 | 15 | 0.160 |
Why?
|
| Cross Infection | 1 | 2020 | 12 | 0.160 |
Why?
|
| Cardiac Tamponade | 1 | 2020 | 1 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 20 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 19 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 104 | 0.160 |
Why?
|
| Sex Factors | 2 | 2019 | 155 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 5 | 0.150 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 10 | 0.150 |
Why?
|
| Arteries | 1 | 2019 | 15 | 0.150 |
Why?
|
| Electric Countershock | 1 | 2019 | 1 | 0.150 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 1 | 0.150 |
Why?
|
| Aspirin | 2 | 2016 | 11 | 0.150 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 3 | 0.150 |
Why?
|
| Reoperation | 1 | 2019 | 17 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 87 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2019 | 1 | 0.150 |
Why?
|
| Electronics | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hydrodynamics | 1 | 2019 | 1 | 0.150 |
Why?
|
| Patients | 1 | 2019 | 3 | 0.150 |
Why?
|
| Certificate of Need | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hospitals | 1 | 2019 | 17 | 0.150 |
Why?
|
| Diastole | 1 | 2018 | 4 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2019 | 17 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 49 | 0.150 |
Why?
|
| Oxygen Radioisotopes | 1 | 2018 | 1 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 83 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2019 | 83 | 0.140 |
Why?
|
| Algorithms | 1 | 2018 | 83 | 0.140 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 3 | 0.140 |
Why?
|
| Software | 1 | 2018 | 18 | 0.140 |
Why?
|
| Hospital Costs | 1 | 2018 | 8 | 0.140 |
Why?
|
| Antithrombins | 1 | 2018 | 1 | 0.140 |
Why?
|
| Hirudins | 1 | 2018 | 1 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2018 | 23 | 0.140 |
Why?
|
| Knowledge | 1 | 2017 | 2 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 5 | 0.130 |
Why?
|
| Amiodarone | 1 | 2017 | 3 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 13 | 0.130 |
Why?
|
| Body Surface Area | 1 | 2016 | 1 | 0.130 |
Why?
|
| Epigastric Arteries | 1 | 2016 | 2 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 11 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 19 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 2113 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2016 | 9 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 82 | 0.120 |
Why?
|
| Radiation Dosage | 2 | 2026 | 8 | 0.120 |
Why?
|
| Radiography | 1 | 2016 | 20 | 0.120 |
Why?
|
| Logistic Models | 1 | 2016 | 165 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 279 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 4 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 8 | 0.120 |
Why?
|
| Pressure | 2 | 2026 | 7 | 0.120 |
Why?
|
| Palpation | 1 | 2015 | 1 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 22 | 0.100 |
Why?
|
| Pericarditis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Sepsis | 1 | 2013 | 6 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 15 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2015 | 121 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2012 | 29 | 0.090 |
Why?
|
| Lipids | 1 | 2012 | 35 | 0.090 |
Why?
|
| Motor Skills | 1 | 2010 | 2 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 9 | 0.080 |
Why?
|
| Risk | 2 | 2020 | 43 | 0.070 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2008 | 2 | 0.070 |
Why?
|
| Pericardium | 1 | 2008 | 16 | 0.070 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 9 | 0.070 |
Why?
|
| Occupational Health | 1 | 2026 | 7 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2025 | 28 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 15 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 58 | 0.050 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2020 | 1 | 0.040 |
Why?
|
| Quality Control | 1 | 2020 | 2 | 0.040 |
Why?
|
| Miniaturization | 1 | 2020 | 1 | 0.040 |
Why?
|
| Laboratories, Hospital | 1 | 2020 | 2 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2020 | 36 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 19 | 0.040 |
Why?
|
| Leadership | 1 | 2020 | 22 | 0.040 |
Why?
|
| Benchmarking | 1 | 2019 | 3 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2019 | 5 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2019 | 8 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 95 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 15 | 0.040 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 2 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 13 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 14 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 55 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2019 | 24 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 101 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 82 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 5 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 4 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 41 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 5 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 42 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 506 | 0.030 |
Why?
|
| Dopamine | 1 | 2015 | 12 | 0.030 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 172 | 0.030 |
Why?
|